Disproportionality analysis highlights gastrointestinal adverse events in patients receiving immune checkpoint inhibitors.
Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are frequently linked to gastrointestinal immune-related adverse events, which can severely affect patient outcomes.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: